BioSpace News Archive

According to Transparency Market Research’s latest report on the global veterinary endoscopes market for the historical period 2017–2018 and forecast period 2019–2027, rapid rise in pet population worldwide is projected to drive the global veterinary endoscopes market during the forecast period.

The global surgical sutures market is primarily driven by increased prevalence’s of chronic diseases. The suture is a tool used in stitching cutaneous wounds and to close surgical opening.

Wilmington, Delaware, United States, Transparency Market Research Inc.: Mobile imaging technology is utilized to give quick, exact analytic administrations on-site, changing a traditionally tedious interaction into a smooth, simple one with prompt outcomes.

Fact.MR, a market research and competitive intelligence provider, mentions that the global medical foam market would be worth US$ 27 Bn in 2022 and grow at the rate of 4% between 2022 and 2032.

Sequana Medical NV announces the completion of enrollment in its Phase 2a SAHARA proof-of-concept study using its first-generation DSR product as treatment for congestive heart failure.

The global hemoglobin A1c testing devices market is estimated to register growth at a CAGR of 10.7% during the forecast period from 2019 to 2027.

ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its second quarter 2022 earnings release and conference call.

Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that it plans to release second quarter 2022 financial and operating results prior to market open on Tuesday, August 2nd, 2022.

Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it had reached agreement with Evening Post Group, LLC (“EPG”) regarding payment, satisfaction and termination of its secured promissory note.

SCYNEXIS, Inc. today announced the presentation of positive outcomes from the CANDLE 304s nested sub-study investigating oral ibrexafungerp in patients with recurrent vulvovaginal candidiasis (RVVC) who failed fluconazole treatment.